Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ: INCY )

72.11 +0.73 (+1.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,514,741
Open 71.66
Bid (Size) 72.11 (4)
Ask (Size) 73.28 (3)
Prev. Close 71.38
Today's Range 71.50 - 72.97
52wk Range 50.35 - 83.95
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
From Genesis Therapeutics, Inc. and Incyte
Via Business Wire
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill

Performance

YTD
+3.71%
+3.71%
1 Month
-0.58%
-0.58%
3 Month
-1.92%
-1.92%
6 Month
+10.67%
+10.67%
1 Year
+19.01%
+19.01%

More News

Read More
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect
Via StockStory
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
What Analysts Are Saying About Incyte Stock
Via Benzinga
Insights into Incyte Q4 Earnings
Via Benzinga
NASDAQ:INCY, an undervalued stock with good fundamentals.
Via Chartmill
What's going on in today's pre-market session: S&P500 movers
Via Chartmill
Why Incyte (INCY) Shares Are Plunging Today
Via StockStory
Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Gapping S&P500 stocks in Monday's session
Via Chartmill
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
Via Benzinga
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
Via StockStory
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
From Incyte
Via Business Wire
Earnings Scheduled For February 10, 2025
Via Benzinga
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
Via StockStory
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Promising Signs: INCYTE CORP Setting the Stage for a Breakout.
Via Chartmill
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
Via Chartmill
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
From Incyte
Via Business Wire
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
Via Benzinga
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.